Literature DB >> 26059654

Comparison of Lower Extremity Edema in Locally Advanced Cervical Cancer: Pretreatment Laparoscopic Surgical Staging with Tailored Radiotherapy Versus Primary Radiotherapy.

Se Ik Kim1,2, Myong Cheol Lim3,4,5, Jeong Seon Lee2, Yeon-Joo Kim2, Sang-Soo Seo2, Sokbom Kang2,6,7, Chong Woo Yoo2,8, Byung-Ho Nam7,9, Joo-Young Kim2,8, Seung Hyun Chung10, Sang-Yoon Park2,6.   

Abstract

BACKGROUND: This study investigated the clinical manifestations of lower extremity edema (LEE) in locally advanced cervical cancer patients treated with two different strategies.
METHODS: In total, 79 cervical cancer survivors with International Federation of Gynecology and Obstetrics stage IB2-IIB were included. Six survivors with stage IB1 and who had been suspicious for lymph node metastasis on pretreatment image also were included. Forty-two patients received radiotherapy after pretreatment laparoscopic surgical staging (Group 1), and 43 patients received primary radiotherapy (Group 2). The patients' medical records and survey results of the Korean version of the Gynecologic Cancer Lymphedema Questionnaire (GCLQ-K) were analyzed.
RESULTS: The incidence of LEE was higher in Group 1 than in Group 2 (69.0 vs. 11.6 %; P < 0.001). The duration of LEE was longer in Group 1 (mean 77.3 vs. 9.4 months). At the time of survey, 47.6 % of the patients in Group 1 were clinically diagnosed with lymphedema compared with no patients in Group 2. In GCLQ-K, the mean symptom cluster scores for general swelling (0.74 vs. 0.09; P < 0.001), limb swelling (0.22 vs. 0.00; P = 0.006), and heaviness (0.45 vs. 0.23; P = 0.033) were significantly higher in Group 1. One patient in Group 1 developed lymphedema-related angiosarcoma that was diagnosed at 7.8 years after surgery.
CONCLUSIONS: Patients with cervical cancer who underwent radiotherapy after laparoscopic surgical staging more commonly experienced LEE and related symptoms than patients who underwent primary radiotherapy. As LEE decreases patients' quality of life, it should be considered during patient consultation and surveillance.

Entities:  

Mesh:

Year:  2015        PMID: 26059654     DOI: 10.1245/s10434-015-4653-6

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  6 in total

1.  General health status of long-term cervical cancer survivors after radiotherapy.

Authors:  Lee Sung Uk; Kim Young Ae; Yoon Young-Ho; Kim Yeon-Joo; Lim Myong Cheol; Park Sang-Yoon; Seo Sang-Soo; Park Ji Eun; Kim Joo-Young
Journal:  Strahlenther Onkol       Date:  2017-05-10       Impact factor: 3.621

2.  Computed tomography-based quantitative assessment of lower extremity lymphedema following treatment for gynecologic cancer.

Authors:  Ji Sung Yoo; Seung Hyun Chung; Myong Cheol Lim; Young Jae Kim; Kwang Gi Kim; Ji Hye Hwang; Yun Hee Kim
Journal:  J Gynecol Oncol       Date:  2016-12-07       Impact factor: 4.401

3.  Development of the short version of the Gynecologic Cancer Lymphedema Questionnaire: GCLQ-7.

Authors:  Se Ik Kim; Namjoo Kim; Seonjoo Lee; Sujung Lee; Jungnam Joo; Sang Soo Seo; Seung Hyun Chung; Sang Yoon Park; Myong Cheol Lim
Journal:  J Gynecol Oncol       Date:  2016-10-07       Impact factor: 4.401

4.  Second primary colorectal cancer among endometrial cancer survivor: shared etiology and treatment sequelae.

Authors:  Myong Cheol Lim; Young-Joo Won; Jiwon Lim; Sang-Soo Seo; Sokbom Kang; Chong Woo Yoo; Joo-Young Kim; Jae Hwan Oh; Robert E Bristow; Sang-Yoon Park
Journal:  J Cancer Res Clin Oncol       Date:  2018-02-14       Impact factor: 4.553

5.  Region-specific Risk Factors for Pelvic Lymph Node Metastasis in Patients with Stage IB1 Cervical Cancer.

Authors:  Jing Zhao; Jing Cai; Hongbo Wang; Weihong Dong; Yuan Zhang; Shaohai Wang; Xiaoqi He; Si Sun; Yuhui Huang; Bangxing Huang; Kay C Willborn; Ping Jiang; Zehua Wang
Journal:  J Cancer       Date:  2021-03-05       Impact factor: 4.207

6.  Lower-Limb Lymphedema after Sentinel Lymph Node Biopsy in Cervical Cancer Patients.

Authors:  David Cibula; Martina Borčinová; Simone Marnitz; Jiří Jarkovský; Jaroslav Klát; Radovan Pilka; Aureli Torné; Ignacio Zapardiel; Almerinda Petiz; Laura Lay; Borek Sehnal; Jordi Ponce; Michal Felsinger; Octavio Arencibia-Sánchez; Peter Kaščák; Kamil Zalewski; Jiri Presl; Alicia Palop-Moscardó; Solveig Tingulstad; Ignace Vergote; Mikuláš Redecha; Filip Frühauf; Christhardt Köhler; Roman Kocián
Journal:  Cancers (Basel)       Date:  2021-05-13       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.